Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Hiit Only

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1/2 (1)
Phase 3 (1)

Trial Status

Recruiting2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Research Network

Common Treatments

  • Hiit Only1
  • Vmd928 Tablet And Pembrolizumab 200 Mg1
  • Vmd928 100 Mg Tablet1
  • Sucralfate1
  • Hiit Record Of Physical Activities At Home1

Active Sponsors

  • Covenant Health Cancer Center1
  • VM Oncology, LLC1
  • Chang Gung Memorial Hospital1

Top Investigators

Related Conditions

  • Esophageal Cancer2
  • Head And Neck Cancers1
  • Head And Neck Cancers Hypopharynx1
  • Radiation Mucositis1
  • Mediastinal Cancer1

Activity Timeline